Treatment Strategy of Meningiomas based on the Pathological Diagnosis

DOI 19 References
  • Oka Hidehiro
    Departments of Laboratory Medicine & Pathology, Mayo Clinic and Mayo Medical School, U. S. A Department of Neurosurgery, Kitasato University School of Medicine
  • Perry Arie
    Department of Pathology, University of California, San Francisco, U. S. A
  • W. Scheithauer Bernd
    Departments of Laboratory Medicine & Pathology, Mayo Clinic and Mayo Medical School, U. S. A

Bibliographic Information

Other Title
  • 病理に基づく髄膜腫の治療方針

Search this article

Description

  Meningioma is a meningothelial (arachnoidal) cell neoplasm, typically attached to the inner surface of the dura mater. Most meningiomas are benign and correspond to WHO grade I. Certain histological subtypes or meningiomas with specific combinations of morphologic parameters are associated with less favourable clinical outcomes and correspond to WHO grade II, including chordoid, clear cell, and atypical meningiomas, and grade III, including papillary, rhabdoid, and anaplastic meningiomas. The treatment strategy for meningiomas is total removal. While benign meningiomas have recurrence rates of about 7-25%, WHO grade II meningiomas recur in 29-52% of cases and grade III meningiomas at rates of 50-94%. Thus, radiotherapy for grade II and III meningiomas after tumor removal may be needed.

Journal

References(19)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top